Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the
upcoming presentation of data highlighting Kyprolis(R) (carfilzomib)
for Injection, a second-generation proteasome inhibitor, and
oprozomib, an oral proteasome inhibitor in early dev...
08:41 AM EDT, 05/17/2013 (MidnightTrader) -- Option implied volatility is mixed into the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) from May 31 to June 4. AbbVie (ABBV) over all option implied volatility of 25 is ab...
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the
upcoming presentations of data highlighting Nexavar(R) (sorafenib)
tablets, Kyprolis(R) (carfilzomib) for Injection, and Stivarga(R)
(regorafenib) tablets across a range of cancers. ...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influenc...
08:27 AM EDT, 05/08/2013 (MidnightTrader) -- Some of the stocks moving on news-driven events in today's pre-market, including their respective trading ranges: UPSIDE MOVERS LEDR: 9.61 to 11.10 MYGN: 28.30 to 30.99 WFM: 92.80 to 100.30 WILC: 6...
04:09 PM EDT, 05/07/2013 (MidnightTrader) -- Onyx Pharmaceuticals (ONXX) is up 2.34% at $92.67 in the after hours session after it reported a Q1 loss of $0.47 per share, and adjusted loss of $0.19 per share, beating the Capital IQ consensus estim...
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its
financial results for the first quarter 2013 and provided a business
update on Kyprolis(R) (carfilzomib) for Injection, Nexavar(R)
(sorafenib) tablets and Stivarga(R) (regorafenib) ta...
06:41 AM EDT, 05/07/2013 (MidnightTrader) -- Earnings Release Date: 05/07/2013 Time: After-hours Avg. Extended-Hours Dollar Volume: $217,187,575 Earnings Sensitivity (up or down): 3.1% Onyx Pharmaceuticals Inc (ONXX) is due to issue its quarterly...